


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A prostaglandin derivative represented by Formula (I):



wherein X is a halogen atom in the α - or β -substitution, Y is an ~~ethylene group, a vinylene group or an ethynylene group~~, R^1 is a C_{3-10} cycloalkyl group, a ~~C_{3-10} cycloalkyl group substituted with a C_{1-4} straight or branched chain alkyl group or a C_{4-13} cycloalkylalkyl group~~, R^2 is a CO_2R^3 group (R^3 is a hydrogen atom, a ~~C_{1-4} straight or branched chain alkyl group or a C_{2-4} straight or branched chain alkenyl group~~), n is an integer of 1 to 42 and p is 0, 1 or 2,

a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. (currently amended): The prostaglandin derivative represented by Formula (I) according to claim 1, wherein X is a chlorine atom in the β -substitution, Y is an ethynylene group, R^1 is a C_{3-10} -cycloalkyl group or a C_{4-13} -cycloalkylalkyl group, R^2 is COOH, n is an integer of 2 and p is 0, a pharmaceutically acceptable salt thereof or a hydrate thereof.

3-7. (canceled).

8. (previously presented): A pharmaceutical composition comprising the prostaglandin derivative according to claim 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.